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Young males have testicular germ cells tumors (TGCT) as the most common malignancy
and its incidence is increasing in several countries. Besides unilateral orchiectomy (UO),
the treatment of TGCT may include surveillance, radiotherapy, or chemotherapy (CT),
basing on tumor histology and stage of disease. It is well known that both radio
and CT may have negative effects on testicular function, affecting spermatogenesis,
and sex hormones. Many reports investigated these aspects in patients treated with
bleomycin, etoposide, and cisplatin (BEP), after UO. In contrast no data are available on
the side effects of carboplatin treatment in these patients. We included in this study
212 consecutive subjects who undergone to sperm banking at our Andrology and
Human Reproduction Unit after UO for TGCT. Hundred subjects were further treated
with one or more BEP cycles (BEP-group), 54 with carboplatin (CARB group), and
58 were just surveilled (S-group). All patients were evaluated for seminal parameters,
sperm aneuploidy, sperm DNA, sex hormones, volume of the residual testis at baseline
(T0) and after 12 (T1) and 24 months (T2) from UO or end of CT. Seminal parameters,
sperm aneuploidies, DNA status, gonadic hormones, and testicular volume at baseline
were not different between groups. At T1, we observed a significant reduction of sperm
concentration and sperm count in the BEP group versus baseline and versus both Carb
and S-group. A significant increase of sperm aneuploidies was present at T1 in the BEP
group. Similarly, the same group at 1 had altered sperm DNA integrity and fragmentation
compared with baseline, S-group and Carb group. These alterations were persistent
after 2 years from the end of BEP treatment. Despite a slight improvement at T2, the
BEP group had still higher percentages of sperm aneuploidies than other groups. No
impairment of sperm aneuploidies and DNA status were observed in the Carb group
both after 1 and 2 years from the end of treatment. Despite preliminary, these data
demonstrate that in selected patients with TGCTs CT with carboplatin represents a
therapeutic option that that seems to not affect sex hormones, spermatogenesis, and
sperm nucleus.
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INTRODUCTION
Young males aged 15–40 years have testicular germ cells tumors
(TGCTs) as the most common malignancy that may affect their
health status (Schmoll et al., 2010; Oldenburg et al., 2013).
It has been reported that about 18,000 European subjects
over reproductive age develop a TGCTs every year (Znaor et al.,
2014) and its incidence is increasing in several countries over
the past 50 years (Huyghe et al., 2007). Many risk factors have
been studied as a pre-disposing factor in the development of this
cancer, but only for some there is a high level of evidence (Garolla
et al., 2012; Ferlin and Foresta, 2014). Early diagnosis and modern
treatment have resulted in over 95% survival rate and improved
quality of life of testicular cancer survivors (Schagen et al., 2008;
Ping et al., 2014).
Usually, treatment for TGCTs is a combination of orchiectomy
and radiation therapy (RT), platinum-based chemotherapy (CT)
or just surveillance, based on tumor histology and stage of
disease. CT including alkylating agents or RT directed to the
gonads are usually used for stage II and relapsed diseases. These
treatments have well-known negative side effects on testicular
functions affecting both spermatogenesis and steroidogenesis up
to oligo/azoospermia and hypogonadism. Moreover a negative
impact of cancer treatments on sperm DNA and chromosomes
has been shown after years from the end of therapy (Tempest
et al., 2008; O’Flaherty et al., 2010; Patassini et al., 2013). It was
proposed that, between CT drugs, etoposide appears to be a good
candidate for aneuploidy sperm induction as it interacts with
topoisomerase II during anaphase I and II of meiosis (De Mas
et al., 2001). Besides the alteration of spermatogenesis, bleomycin,
etoposide and cisplatin (BEP)-use has been reported to affect
sperm chromosome and DNA status (De Mas et al., 2001). These
authors, investigating sperm cell aneuploidy for chromosomes 7,
16, 18, X, and Y in a cohort of BEP-treated TGCTs described
a significant increase in the frequency of diploidy and disomy
for these chromosomes compared to healthy controls. In a
subsequent study done in a population of TGCTs patients,
Tempest et al. (2008) documented an increase of aneuploidies
for sperm chromosomes, X, Y, 13, and 21, 6 months after the
end of 2–4 BEP cycles that decline to pretreatment levels only
at 18 months after the end of treatment. Based on these findings,
some authors suggested that treated patients should be counseled
to avoid conceptions up to 2 years after the end of treatments
(Hassold et al., 1996; Tempest et al., 2008).
Exposure to the treatment regimen for testis cancer (BEP
or cyclophosphamide) causes DNA damage, inducing cross-
links as well as single and double strand breaks: therefore
these treatments may represent a potential risk to subsequent
generations if DNA and telomere damage in sperm are sustained;
moreover it was reported that significant sperm DNA damage
and reduced chromatin compaction persisted in men for up
to 24 months after BEP treatment (Zhou and Bartek, 2004;
O’Flaherty et al., 2010; Liu et al., 2015). Recently Liu et al.
(2015) demonstrated that in vivo exposure of rat male germ
cells to a BEP regimens, analogous to that given to testis
cancer patients, induces telomere shortening in all stages of
spermatogenesis raising concern about the potential risk of BEP
exposure to subsequent generations. Interestingly DNA double
strand breaks were increased significantly in zygotene rat male
germ cells exposed to BEP regimens, as assessed by gamma-
H2AX immunofluorescence (Liu et al., 2015). Furthermore a
marked increase in DNA Fragmentation Index after 3 and
6 months to the end of BEP treatment was demonstrated in a
series of TGCTs patients, improving after 12 and 24 months to
the end of treatments (Paoli et al., 2015).
On this basis, patients candidate to CT usually receive
medical counseling about sperm preservation, endocrine follow-
up and genetic counseling to avoid conceptions during the
treatments period up to 2 years after the end of therapy aimed to
avoid possible defective genome transmission to their offspring
(Tempest et al., 2008; Ping et al., 2014). Despite some authors
raised concern about the hypothesis that spermatozoa may carry
damages DNA even long after treatments have finished, there is
no actual evidence to suggest that previous TGCTs treatments are
associated with birth defect (Thomson et al., 2002; Ping et al.,
2014).
Because most patients and their parents are interested to
preserve fertility, sperm banking should be recommended before
cancer treatments (Jeruss and Woodruff, 2009). Although sperm
cryopreservation allow cancer survivors to reach fertility with
in vitro fertilization (IVF), new treatment strategies with a
lower impact on testicular function are challenging to preserve
spontaneous fertility and to reduce sperm DNA alterations and
hormones impairments avoiding potential hypogonadism (Choy
and Brannigan, 2013). Many reports have investigated the impact
on testicular function and in particular on spermatogenesis of RT
and CT with BEP in men before and after orchiectomy (Thomson
et al., 2002; Bujan et al., 2013; Choy and Brannigan, 2013). In
contrast no data are available on the effects of a carboplatin
(CARB)-based CT on these topics and, in particular, no data are
available on the comparison between BEP-treated and CARB-
treated subjects.
Aim of the present study was to assess the impact of
orchiectomy followed by CT (BEP treatment, or surveillance
alone on sperm parameters, sperm aneuploidies and DNA
fragmentation, sex hormones, and testicular volume in TGCTs
cancer patients at basal and at 12 and 24 months after the end
of any treatment. In particular, we aimed to evaluate the possible
gonadotoxic effects of CARB in comparison with surveillance and
BEP treatments.
MATERIALS AND METHODS
Subjects
This retrospective study enrolled 212 consecutively subjects
who had been sent by oncologist to Unit of Andrology and
Reproductive Medicine of Padua for sperm banking after
unilateral orchiectomy (UO) for TGCTs. Patients had a cancer
stage ranging from first to third. The subjects were divided into
three groups based on the management of disease suggested by
the oncologist: 100 with one to four BEP cycles based on tumor
histology, 54 with CARB one cycle (group 3), and 58 had no
treatment (surveillance alone). Patients were evaluated at baseline
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(T0) and then followed-up after 12 and 24 months from the start
of treatments (T1 and T2, respectively) for sperm parameters,
sex hormones, testicular volume, sperm aneuploidies, and DNA
integrity. We have excluded from the study patients with know
causes of infertility such as Klinefelter syndrome, Y chromosome
microdeletions, varicocele in the remaining testis and history
of orchitis or cryptorchidism. Written informed consent was
obtained from all patients, and the study protocol was approved
by the local ethics committee.
Semen Sample Collection and
Processing
Semen samples were obtained by masturbation after 2–5 days of
sexual abstinence. After liquefaction at room temperature, semen
volume, pH, sperm concentration, total sperm count (TSC),
viability, motility, and normal morphology were determined
according to World Health Organization guidelines for semen
analysis (World Health Organization [WHO], 1999). Semen
samples were then washed three times with sterile phosphate-
buffered saline (PBS 1), and the pellet was used for the subsequent
analyses.
Hormone Assay
Blood sample was collected in the fasting state between 08.00 and
1000 h. Serum FSH, LH, and total testosterone were evaluated by
commercial electrochemiluminescence immunoassay methods
(Elecsys, 2010; Roche Diagnostics, Mannheim, Germany) as
reported elsewhere (Selice et al., 2011). For all parameters, the
intra- and inter-assay coefficients of variation were <8 and 10%,
respectively).
Ultrasound (US) Scanning
To evaluate testicular size, morphology and normal tissue echo
pattern, all subjects were studied with ultrasonography. All
US examinations were made using a high resolution machine
(Aplio XV Toshiba, Tokyo, Japan) equipped with a 7–13 MHz
multifrequency linear probe by the same experienced doctor
(P.P.). Intra-observer variability for testicular volume was
estimated to be less than 10% as reported in a previous study of
our group (Selice et al., 2011).
FISH Analysis for Sperm Aneuploidy
The study of sperm aneuploidy was performed by multicolor
FISH, as reported elsewhere (Garolla et al., 2013). The
DNA hybridization was performed using a human satellite
probe-specific mix for chromosomes X, Y, and 18 (Kreatech
Diagnostics). Probes were direct-labeled with fluorochrome
PlatinumBright495 for chromosome X, resulting in a green
signal and fluorochrome PlatinumBright550 for chromosome
Y, resulting in a red signal, for the detection of chromosome
18 a PlatinumBright415 direct-labeled specific probe was used,
resulting in a blue signal.
The DNA denaturation of sperm and probes, incubation,
posthybridization washing, and nuclear staining were performed
according to the Kreatech protocol. After preparation, slides
were observed using a fluorescence microscope (Nikon Eclipse
E600) equipped with a triple band-pass filter set [fluorescein
isothiocyanate (FITC), tetrarhodamine isothiocyanate (TRITC),
6-diamino-2-phenylindole (DAPI)]. Single spots were evaluated
as reported elsewhere (Robbins et al., 1995). For each patient, at
least 2,500 cells were scored.
Acridine Orange Test (AO Test)
The AO test was used to assess the heterogeneity of sperm
DNA. Briefly 10 µl of semen sample and equal volume of AO
solution [10 mL acridine orange stain (1%) was mixed with
2.5 mL Na2HPO4.7H2O (0.3 mol/l), and 40 mL citric acid
(0.1 mol/l)] were mixed together on the surface of a glass slide
and covered with a glass coverslip. The sample was then evaluated
with a fluorescence microscope with a 490 nm excitation light
and 530 nm barrier filter. Nuclei from 200 spermatozoa were
examined and scored as with green- or red-fluorescence. When
the head showed green fluorescence, sperm were considered
normal (double-stranded DNA); they were considered denatured
when fluorescence was red (single-stranded DNA). Results were
expressed as the percentage of sperm that showed altered (red)
fluorescence (Eggert-Kruse et al., 1996).
TUNEL Assay
The DNA fragmentation was evaluated by TUNEL assay
performed with the Cell Death Detection Kit (Roche
Diagnostics). Fluorescein isothiocyanate–deoxyuridine
triphosphate was used as label according to the manufacturer’s
instructions and counterstained with 40,6-diamidino-2-
phenylindole. Briefly, after preparation, sperm samples were
smeared on microscope slides, fixed with 4% paraformaldehyde,
and permeabilized with 0.1% Triton X-100 in 0.1% sodium
citrate. The specimens were incubated in TUNEL reaction
mixture in a humidified atmosphere for 60 min at 37◦C in
the dark. The slides were rinsed twice, and then 1 mL 40,6-
diamidino-2-phenylindole was added to counterstain the cells.
Four hundred spermatozoa were analyzed at 40 by using a
Nikon E600 epifluorescence light microscope equipped with
a 450–490-nm excitation (Nikon), and those cells with green
fluorescence were considered to be altered.
γH2AX Flow-Cytometric Analysis
The sperm cells were fixed, permeabilized, washed in PBS and
centrifuged as reported in the previous paragraph. Thereafter,
pellets were resuspended in 200 µl of PBS-0.1% BSA and equally
split in two vials used as samples and negative controls. The
staining for γH2AX was conducted resuspending the pellet
samples in 200 µl of polyclonal rabbit anti-γH2AX antibody
(1:200 dilution), (Millipore, Billerica, MA, USA) for 90 min at
37◦C. Negative controls and samples were then rinsed in PBS-
0.1% BSA solution and after centrifugation were resuspended in
200 µl of secondary goat anti-rabbit IgG-fluorescein conjugated
antibody (1:400 dilutions; Millipore, Billerica, MA, USA) for
45 min at 37◦C. Finally, the sperm cells were rinsed once in
PBS-0.01% tween-20 solution (Sigma–Aldrich, St. Louise, MO,
USA) for 5 min at room temperature and centrifuged. Pellet was
washed once in a PBS solution for 5 min at room temperature
and centrifuged. Before analysis with a Flow Cytometer cells were
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resuspended in 300 µl of Propidie Iodide solution (25 ng/m of
PI in H2O; Sigma–Aldrich, St. Louise, MO, USA). Samples were
then analyzed on a FACScan flow cytometer (Becton Dickinson,
Mountain View, CA, USA) equipped with a 15 mW – 488 nm,
air cooled, argon ion laser for excitation. For each sample,
40 000 events were recorded within the characteristic flame-
shaped region in the forward scatter/side scatter (FSC/SSC) dot
plot. Data were acquired and analyzed with Cellquest analysis
software. The average amount of γH2AX antibody staining
relative to the untreated control was scored as the percentage
of spermatozoa having fluorescence intensities above a threshold
excluding ≤1% of the events in the negative sample (Li et al.,
2006). Results were expressed as percentage of DSBs in total
sperm analyzed.
Statistical Analysis
Results are expressed as mean ± SD. Variations in semen and
hormonal parameters and testicular volume were considered and
are expressed as raw differences.
Comparisons among four groups were performed through
ANOVA test. To evaluate effects of therapy along time, two-
sample t-tests were computed using T0 as reference time point.
To compare therapies, also considering the initial individual
characteristics, a repeated measures ANOVA is performed for
each parameter of interest. The software package R (R Core
Team, 2012) was used for statistical analyses. Probability values
of<0.05 were considered statistically significant.
RESULTS
Mean age of different groups was not significantly different
(S= 32.0± 1.4, CARB= 34.2± 3.5, BEP= 34.0± 2.8 years).
In Table 1 are reported seminal parameters, hormonal levels,
and testicular volume at different time points of the study of
surveilled patients (S) and patients treated with CARB or BEP
observed at different time points of the study. At baseline, seminal
parameters, hormonal status, and testicular volume did not differ
between three groups. At T1 the BEP group had a significant
reduction of sperm concentration and sperm count compared
with baseline (p < 0.0001) and versus both CARB and S-group
(p < 0.0001). At T2, these semen alterations were still evident
in BEP patients compared with other groups. All groups showed
no significant variations in sperm motility and morphology
during the whole study. After orchiectomy, all groups showed
a progressive increase of FSH plasma levels. In treated patients
(both CARB and BEP groups), this change was already significant
at T1 (p < 0.001 versus T0) while S-group showed a significant
increase only at T2. In contrast, LH, total testosterone, and
testicular volume remained unchanged in all groups.
Table 2 shows results of FISH test to evaluate sperm
aneuploidies (autosomes, sex chromosomes, and total
aneuploidies), acridine orange, TUNEL and γH2AX tests
to evaluate, respectively, DNA compaction, single- or double-
strand fragmentation and double-strand fragmentation. No
differences between groups were observed at baseline. When, we
considered FISH analysis for autosome and sex chromosomes TA
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TABLE 2 | Sperm aneuploidies and nuclear status observed in different groups at baseline, T1 and T2.
FISH (Aut.) (%) FISH (Sex) (%) FISH (Tot.) (%) Acridine orange (%) TUNEL (%) γH2AX (%)
S-T0 0.61 ± 0.32 0.73 ± 0.52 1.34 ± 0.76 19.78 ± 4.0 16.13 ± 4.16 5.35 ± 3.35
S-T1 0.64 ± 0.27 0.68 ± 0.28 1.33 ± 0.47 19.52 ± 3.59 15.74 ± 4.36 6.04 ± 3.3
S-T2 0.65 ± 0.29 0.65 ± 0.30 1.29 ± 0.44 18.87 ± 4.05 15.09 ± 4.66 6.13 ± 3.14
Carb-T0 0.69 ± 0.26 0.72 ± 0.36 1.41 ± 0.50 20.21 ± 4.4 16.38 ± 3.88 6.12 ± 2.88
Carb-T1 0.69 ± 0.19 0.61 ± 0.24 1.30 ± 0.35 18.83 ± 4.65 16.21 ± 4.1 6.79 ± 3.93
Carb-T2 0.69 ± 0.22 0.60 ± 0.27 1.29 ± 0.36 17.29 ± 4.68 16.0 ± 4.53 6.58 ± 3.75
BEP-T0 0.69 ± 0.35 0.8 ± 0.4 1.49 ± 0.68 20.18 ± 5.64 16.94 ± 5.22 6.97 ± 4.58
BEP-T1 1.08 ± 0.61 1.19 ± 0.78 2.27 ± 1.38∗# 25.43 ± 6.17∗# 21.49 ± 4.94∗# 11.42 ± 4.28∗#
BEP-T2 0.83 ± 0.41 0.88 ± 0.54 1.9 ± 0.89◦$ 22.42 ± 5.02∗$ 20.64 ± 5.2∗# 10.09 ± 3.34∗∗
Aut, autosomes (13,18,21); Sex, sex chromosomes (X,Y); Tot., all chromosomes; S, surveillance; Carb, carboplatin; BEP, bleomicin, etoposide, and platinum; T0, after
orchiectomy; T1, 1 year after orchiectomy or after end of CT; T2, 2 years after orchiectomy or after end of CT. ∗p < 0.0005 vs. T0, #p < 0.0005 vs. Carb T1, ◦p < 0.01
vs. T0, $p < 0.01 vs. carb T2, ∗∗p < 0.05 vs. T0 and Carb T2.
separately data were not different in all groups along the
study. However, considering autosomes and sex chromosomes
as a whole, BEP subjects showed significantly higher sperm
aneuploidies at T1 (p < 0.01 vs. T0 and CARB- group). This
alteration was slightly reduced at T2, even if the aneuploidy rate
in BEP group was still significantly higher than in other groups
(p < 0.05). Similarly to sperm aneuploidies, at T1 sperm DNA
compaction and fragmentation (both single- and double strand
breaks) of BEP group were significantly impaired compared to
baseline, S- and CARB group. These alterations were persistent
after 2 years from the end of BEP treatment. No impairments of
sperm aneuploidies, DNA compaction and fragmentation were
observed in the CARB group both after 1 and 2 years from the
end of treatment. In this study, we found no factor able to predict
changes of sperm parameters, sperm nucleus, and hormones in
the response to CT.
In Figure 1 are reported some examples of different tests
performed to evaluate sperm nuclear status in surveillance and
CT treated patients. Figures 1c,d and thin lines of Figures 1e,f
show examples of sperm from BEP patients.
DISCUSSION
Testicular cancer is the most frequent malignancy affecting males
at reproductive age. It has been reported that a significant number
of European subjects over reproductive age develop a TGCTs
every year (Znaor et al., 2014) and its incidence is increasing in
several countries over the past 50 years (Huyghe et al., 2007).
Actually the new therapeutic strategies and follow-up allow
survivorship in over 95% of cases. After inguinal orchiectomy
patients can be treated by RT on pelvic lymph nodes, CT
or simply surveilled on the basis of tumor histology, staging,
prognostic factors, and patients decision after oncological
counseling. Combined therapy with etoposide, cisplatin, and
bleomycin is largely considered a useful and effective option for
the treatment of TGCTs (Oldenburg et al., 2013).
In 2005 it has been introduced the possibility of treatment
with CARB alone in selected cases of TGCTs (seminomas and
first stage of disease). Moreover, it has been demonstrated the
non-inferiority of such treatment compared with RT, especially
FIGURE 1 | Example of different tests performed to evaluate sperm
nuclear status in surveillance and chemotherapy (CT) treated patients
(Carb and PEB). (a,c) Examples of normal and altered sperm compaction.
(b,d) Examples of euploid (18, Y) and aneuploid sperm (18, X, and Y).
(e) Examples of single/double strand breaks observed in different groups.
(f) Examples of double strand breaks observed in different groups.
with regard to the disease-free period (Oliver et al., 2005). The
risk of second malignancy like non-testicular germ cell has
been associated with moderate-dose infradiaphragmatic RT in
stage I seminoma. Further data by a subsequent study have
later confirmed these findings (Oliver et al., 2011) and were
followed by a broad scientific debate on the effectiveness of
one cycle of CARB compared with RT. In particular, the matter
of debate was the methodology to study renal function for
decisions about CARB dose (Dieckmann et al., 2011; Stenning
et al., 2011). Recently, this aspect has been definitely clarified and
the gold standard for GFR measurement and consequently dose
calculation of adjuvant CARB CT is considered (51)Cr-EDTA
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(Quinton et al., 2013). Based on this evidence, the number of
people suffering from TGCTs treated with one cycle CARB alone
has increased in recent years.
It is far known that conventional CT regimens used in TGCTs
patients as BEP, may affect male fertility and endocrine function
of the residual testis (Hassold et al., 1996; Tempest et al., 2008;
Bujan et al., 2013). Moreover, BEP use has been reported to
affect sperm chromosomes and to alter DNA status (De Mas
et al., 2001; Zhou and Bartek, 2004; Liu et al., 2015; Paoli et al.,
2015). In contrast, no data are available regarding the impact of
treatment with CARB on gonadal function. In this preliminary
study, we evaluated for the first time the effect of one cycle CARB
on semen parameters, sex hormones, sperm aneuploidies, and
DNA status in a group of TGCTs patients treated with BEP or
one cycle of CARB followed at 12 (T1) and 24 months (T2) after
therapy. A third group of TGCTs patients in which oncologist
suggested only surveillance after orchiectomy, served as a control
group (S-group). Our results confirmed that BEP treatment has
a detrimental effect on sperm parameters. In contrast, therapy
with CARB alone seems to not affect semen quality. In fact, as in
surveillance patients, semen parameters, hormones, and volume
of the residual testis remained unchanged. Moreover, our findings
showed an increase of sperm aneuploidies after BEP-therapy
and these alterations persisted upon 24 months after the end of
treatment. Moreover, we observed negative effects of BEP therapy
on sperm DNA integrity, persisting upon 24 months from the
end of treatments. In our experience, CARB use did not affect
sperm aneuploidies, DNA compaction, and DNA fragmentation
at any time of the study. Basing also on these results and the risk
of second tumors (non-TGCT0), in patients treated with RT, the
use of CARB mono-CT is suggested in selected patients (tumor
histology, stage of disease, and prognostic factors) with TGCTs.
CONCLUSION
Our results although preliminary, denote that CARB alone seems
not to have a negative effect on fertility and sex hormones in
selected TGCTs patients. Despite the small amount of patients
and the need of larger studies to confirm our data, the present
study is the first on this topic suggesting that one cycle
CARB, besides representing a valid therapeutic option, seem to
not affect spermatogenesis, sperm aneuploidies, DNA integrity,
and gonadal hormones in TGCTs orchidectomized patients.
Moreover, the multidisciplinary approach is mandatory to choose
the best treatment in patients with cancer disease potentially
curable (Berretta et al., 2014).
AUTHOR CONTRIBUTIONS
Selected the patients: MG, MB, AG, PP, and RS. Conceived and
designed the experiments: MG, AG, and CF. Performed the
experiments: AB, PP, BS, and IC. Analyzed the data: MG, LF, and
AG. Contributed reagents/materials/analysis tools: AB, IC, BS,
and PP. Wrote and revised the manuscript: MG, MB, CF, and AG.
REFERENCES
Berretta, M., Di Francia, R., and Tirelli, U. (2014). Editorial – The new oncologic
challenges in the 3RD millennium. W.C.R.J. 1:e133.
Bujan, L., Walschaerts, M., Moinard, N., Hennebicq, S., Saias, J., Brugnon, F.,
et al. (2013). Impact of chemotherapy and radiotherapy for testicular
germ cell tumors on spermatogenesis and sperm DNA: a multicenter
prospective study from the CECOS network. Fertil. Steril. 100, 673–680. doi:
10.1016/j.fertnstert.2013.05.018
Choy, J. T., and Brannigan, R. E. (2013). The determination of reproductive safety
in men during and after cancer treatment. Fertil. Steril. 100, 1187–1191. doi:
10.1016/j.fertnstert.2013.05.018
De Mas, P., Daudin, M., Vincent, M. C., Bourrouillou, G., Calvas, P., Mieusset, R.,
et al. (2001). Increased aneuploidy in spermatozoa from testicular tumour
patients after chemotherapy with cisplatin, etoposide and bleomycin. Hum.
Reprod. 16, 1204–1208. doi: 10.1093/humrep/16.6.1204
Dieckmann, K. P., Matthies, C., and Kliesch, S. (2011). Carboplatin does not
prevent contralateral testicular tumors in patients with seminoma. J. Clin.
Oncol. 29, 2944–2945. doi: 10.1200/JCO.2011.35.7970
Eggert-Kruse, W., Rohr, G., Kerbel, H., Schwalbach, B., Demirakca, T., Klinga, K.,
et al. (1996). The Acridine Orange test: a clinically relevant screening method
for sperm quality during infertility investigation? Hum. Reprod. 11, 784–789.
doi: 10.1093/oxfordjournals.humrep.a019255
Ferlin, A., and Foresta, C. (2014). Testis cancer: genes, environment, hormones.
Front. Endocrinol. (Lausanne) 5:172. doi: 10.3389/fendo.2014.00172
Garolla, A., Pizzol, D., Bertoldo, A., De Toni, L., Barzon, L., and Foresta, C. (2013).
Association, prevalence and clearance of human papillomavirus and antisperm
antibodies in infected semen samples from infertile patients. Fertil. Steril. 99,
125–131. doi: 10.1016/j.fertnstert.2012.09.006
Garolla, A., Pizzol, D., Bertoldo, A., Ghezzi, M., Carraro, U., Ferlin, A., et al. (2012).
Testicular cancer and HPV semen infection. Front. Endocrinol. (Lausanne)
3:172. doi: 10.3389/fendo.2012.00172
Hassold, T., Abruzzo, M., Adkins, K., Griffin, D., Merrill, M., Millie, E., et al. (1996).
Human aneuploidy : incidence, origin and etiology. Environ. Mol. Mutagen 28,
167–175. doi: 10.1002/(SICI)1098-2280(1996)28
Huyghe, E., Plante, P., and Thonneau, P. F. (2007). Testicular cancer
variations in time and space in Europe. Eur. Urol. 51, 621–628. doi:
10.1016/j.eururo.2006.08.024
Jeruss, J. S., and Woodruff, T. K. (2009). Preservation of fertility in patients with
cancer. N. Engl. J. Med. 360, 902–911. doi: 10.1056/NEJMra0801454
Li, Z., Yang, J., and Huang, H. (2006). Oxidative stress induces H2AX
phosphorylation in human spermatozoa. FEBS Lett. 580, 6161–6168. doi:
10.1016/j.febslet.2006.10.016
Liu, M., Maselli, J., Hales, B. F., and Robaire, B. (2015). The effects of chemotherapy
with bleomycin, etoposide and cis-platinum on telomeres in rat male germ cells.
Andrology 3, 1104–1112. doi: 10.1111/andr.12102
O’Flaherty, C., Hales, B. F., Chan, P., and Robaire, B. (2010). Impact of
chemotherapeutics and advanced testicular cancer or Hodgkin lymphoma
on sperm deoxyribonucleic acid integrity. Fertil. Steril. 94, 1374–1379. doi:
10.1016/j.fertnstert.2009.05.068
Oldenburg, J., Fossa, S. D., Nuver, J., Heidenreich, A., Schmoll, H. J., Bokemeyer, C.,
et al. (2013). Testicular seminoma and non-seminoma: ESMO clinical practice
guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 24(Suppl. 6),
125–132. doi: 10.1093/annonc/mdt304
Oliver, R. T., Mason, M. D., Mead, G. M., von der Maase, H.,
Rustin, G. J., Joffe, J. K., et al. (2005). Radiotherapy versus single-
dose carboplatin in adjuvant treatment of stage I seminoma: a
randomised trial. Lancet 366, 293–300. doi: 10.1016/S0140-6736(05)
66984-X
Oliver, R. T., Mead, G. M., Rustin, G. J., Joffe, J. K., Aass, N., Coleman, R.,
et al. (2011). Randomized trial of carboplatin versus radiotherapy for stage
I seminoma: mature results on relapse and contralateral testis cancer rates
in MRC TE 19/EORTC 30982 study. J. Clin. Oncol. 29, 957–962. doi:
10.1200/JCO.2009.26.4655
Frontiers in Pharmacology | www.frontiersin.org 6 May 2016 | Volume 7 | Article 122
fphar-07-00122 May 11, 2016 Time: 12:6 # 7
Ghezzi et al. BEP in Testicular Germ Cell Tumor
Paoli, D., Gallo, M., Rizzo, F., Spanò, M., Leter, G., Lombardo, F., et al.
(2015). Testicular cancer and sperm DNA damage: short- and long-term
effects of antineoplastic treatment. Andrology 3, 122–128. doi: 10.1111/j.2047-
2927.2014.00250.x
Patassini, C., Garolla, A., Bottacin, A., Menegazzo, M., Speltra, E., Foresta, C., et al.
(2013). Molecular karyotyping of human single sperm by array-comparative
genomic hybridization. PLoS ONE 8:922. doi: 10.1371/journal.pone.006
0922
Ping, P., Gu, B. H., Li, P., Huang, Y. R., and Li, Z. (2014). Fertility outcome of
patients with testicular tumor: before and after treatment. Asian J. Androl. 16,
107–111. doi: 10.4103/1008-682X.122194
Quinton, A., Lewis, P., Ali, P., Morgan, C., and Bertelli, G. (2013). A comparison
of measured and estimated glomerular filtration rate for carboplatin dose
calculation in stage I testicular seminoma. Med. Oncol. 30:661. doi:
10.1007/s12032-013-0661-1
Robbins, W. A., Baulch, J. E., Moore, D. II, Weyer, H. U., Blakey, D., and
Wyrobek, A. J. (1995). Three-probe fluorescent in-situ hybridization to assess
chromosome X, Y and 8 aneuploidy in sperm of 14 men from two healthy
groups: evidence for a paternal age effect on sperm aneuploidy. Reprod. Fertil.
Dev. 7, 799–809. doi: 10.1071/RD9950799
Schagen, S. B., Boogerd, W., Muller, M. J., Bokkel Huinink, W. T., Moonen, L.,
Meinhardt, W., et al. (2008). Cognitive complaints and cognitive impairment
following BEP chemotherapy in patients with testicular cancer. Acta Oncol. 47,
63–70. doi: 10.1080/02841860701518058
Schmoll, H. J., Jordan, K., Huddart, R., Laguna Pes, M. P., Horwich, A., Fizazi, K.,
et al. (2010). Testicular non seminoma: ESMO Clinical practice guidelines for
diagnosis, treatment and follow-up. Ann. Oncol. 21(Suppl. 5), 147–154. doi:
10.1093/annonc/mdq177
Selice, R., Ferlin, A., Garolla, A., Caretta, N., and Foresta, C. (2011).
Effects of endogenous FSH on normal human spermatogenesis in
adults. Int. J. Androl. 34, e511–e517. doi: 10.1111/j.1365-2605.2010.
01134.x
Stenning, S., Oliver, T., Mead, B., and Gabe, R. (2011). Carboplatin in clinical
stage I seminoma: a valuable option for patient management. J. Clin. Oncol.
29, 4210–4211. doi: 10.1200/JCO.2011.36.2434
Tempest, H. G., Ko, E., Chan, P., Robaire, B., Rademaker, A., and Martin, R. H.
(2008). Sperm aneuploidy frequencies analysed before and after chemotherapy
in testicular cancer and Hodgkin’s lymphoma patients. Hum. Reprod. 23,
251–258. doi: 10.1093/humrep/dem389
Thomson, A. B., Campbell, A. J., Irvine, D. S., Anderson, R. A., Kelnar, C. J. H.,
Hamish, W., et al. (2002). Semen quality and spermatozoal DNA integrity in
survivors of childhood cancer: a case-control study. Lancet 360, 361–367. doi:
10.1016/S0140-6736(02)09606-X
World Health Organization [WHO] (1999). WHO Laboratory Manual for
the Examination of Human Semen, and Sperm-Cervical Mucus Interaction.
Cambridge: Cambridge University Press.
Zhou, B. B., and Bartek, J. (2004). Targeting the checkpoint kinases:
chemosensitization versus chemoprotection. Nat. Rev. Cancer 4, 216–225.
doi: 10.1038/nrc1296
Znaor, A., Lortet-Tieulent, J., Jemal, A., and Bray, F. (2014). International
variations and trends in testicular cancer incidence and mortality. Eur. Urol.
65, 1095–1106. doi: 10.1016/j.eururo.2013.11.004
Conflict of Interest Statement: The authors declare that the research was
conducted in the absence of any commercial or financial relationships that could
be construed as a potential conflict of interest.
Copyright © 2016 Ghezzi, Berretta, Bottacin, Palego, Sartini, Cosci, Finos, Selice,
Foresta and Garolla. This is an open-access article distributed under the terms
of the Creative Commons Attribution License (CC BY). The use, distribution or
reproduction in other forums is permitted, provided the original author(s) or licensor
are credited and that the original publication in this journal is cited, in accordance
with accepted academic practice. No use, distribution or reproduction is permitted
which does not comply with these terms.
Frontiers in Pharmacology | www.frontiersin.org 7 May 2016 | Volume 7 | Article 122
